Cellebrite DI (CLBT) Operating Expenses (2020 - 2025)

Cellebrite DI's Operating Expenses history runs 6 years deep, the most recent figure standing at $88.3 million for Q4 2025.

• In Q4 2025, Operating Expenses rose 16.68% year-over-year to $88.3 million; the TTM figure through Dec 2025 stood at $334.0 million (up 18.57% YoY), while the FY2025 annual figure was $334.0 million, up 18.57% from the prior year.
• Operating Expenses was $88.3 million for Q4 2025 at Cellebrite DI, up from $86.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $88.3 million in Q4 2025 to a low of $40.7 million in Q1 2021.
• Historically, Operating Expenses has averaged $63.2 million across 5 years, with a median of $58.9 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Operating Expenses surged 64.07% in 2021, then dropped 0.69% in 2023.
• A 5-year view of Operating Expenses shows it stood at $51.3 million in 2021, then increased by 1.85% to $52.2 million in 2022, then advanced by 20.85% to $63.1 million in 2023, then advanced by 19.97% to $75.7 million in 2024, then gained by 16.68% to $88.3 million in 2025.
• The last three Operating Expenses figures came in at $88.3 million (Q4 2025), $86.7 million (Q3 2025), and $81.2 million (Q2 2025), per Business Quant data.